Patent Application
20160326600
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 23, 2015, is named 14-21001-WO(260947.00244)_SL.txt and is 42,800 bytes in size.
The detection of specific DNA and RNA sequences has many uses in clinical diagnostic, scientific research, and agricultural markets. For example, the detection of cancer driver mutations, bacteria/virus subtypes, and single nucleotide polymorphism (SNP) is important for both health and research purposes. The detection methods could either use standard PCR assays to detect the sequence of interest from a well-mixed solution, or they could use in situ hybridization (ISH) approaches that provide the localization patterns of DNA and RNA. In the agricultural industry, nucleic acid detection could be used for genotyping viruses and bacteria that may potentially lead to foodborne diseases (e.g. Salmonella), and for identifying genetically modified organisms (GMO).
One major limitation of many previous DNA and RNA detection technologies is the requirement of expensive equipment and/or reagents. The development of inexpensive reagents that could be used in conjunction with inexpensive equipment would improve the throughput of scientific progress, facilitate inexpensive clinical diagnostics, and encourage more consistent agricultural screening.
A large driver of reagent cost is the need to use different functionalized oligonucleotides for quantitation and/or visualization of different target sequences. Large pools of functionalized oligonucleotides are expensive to synthesize because of low synthesis yield and purification steps, but are frequently used in nucleic acid biotechnologies. Therefore, a universal functionalized sequence that can be used for the assaying of a variety of nucleic acid sequences would significantly reduce the reagent cost.
The probe system of the present disclosure comprises a universal component and a target dependent component. The universal component comprises at least a first universal oligonucleotide/strand and in some embodiments, a second universal oligonucleotide/strand. The first and second universal strands each comprise one region and in some embodiments, two regions. The first and second universal strands comprise sequence that is not target specific and therefore can be used with any target dependent component. The target dependent component comprises a protector strand and a target-specific/complement strand. The protector strand comprises at least one region and in some embodiments, two or more regions. One or more regions of the protector strand is at least partially complementary (and in some instances fully complementary) to at least a portion of the second universal strand and can form a first double-stranded region. The target-specific strand (i.e. complement strand) comprises at least two regions and in some instances three or more regions. At least one of the regions of the target-specific strand is fully or partially complementary to the at least one region of the first universal strand and may give rise to a second double-stranded region. In some instances, the protector strand has a region that is at least partially complementary (and in some instances fully complementary) to all or a portion of the target-specific strand and may give rise to a third double-stranded region. The target-specific strand contains another region that is not hybridized to any other strand of the probe, but is complementary to a portion of the target sequence. To be clear, the region of the target-specific strand that is complementary to a region of the protector strand is also complementary to the target sequence. The first universal strand may comprise a further region that is fully or partially complementary to the second universal strand which may give rise to a fourth double-stranded region. In some embodiments, the first universal strand comprises a label conjugated thereto. In other embodiments, the second universal strand comprises a moiety that prevents detection of the label prior to hybridization of the probe to the target sequence.
Upon hybridization of the probe to the target nucleic acid, the protector strand and any universal strand hybridized thereto dissociates from the target-specific strand leaving the target-specific strand, along with any universal strand hybridized thereto, hybridized to the target nucleic acid. Thus, the probes of the present disclosure permit the use of functionalized universal components with a variety of target dependent components thereby eliminating the expense of synthesizing a different functionalized probe for each desired target sequence.
The present disclosure generally relates to nucleic acid probes, and more specifically, to nucleic acid probes comprising a universal component and a target dependent component.
One advantage of the present probe system is that the universal oligonucleotide is decoupled from the target nucleic acid specificity such that the same universal oligonucleotide can be produced for probes having specificity for a variety of related or unrelated nucleic acid sequences. Furthermore, the sequences of the universal component (and the regions of the target dependent component that complement the universal component) are formed of arbitrary sequence to avoid the formation of unintended hybridization products with other nucleic acids in the sample. The term “arbitrary” is only intended to mean that the sequence is designed to not hybridize with any nucleic acid molecules in a sample beyond the nucleic acid strands/oligonucleotides used to form the probe.
The target dependent component is synthesized for the desired target without requiring specialized synthesis of the universal component, which in many instances may comprise a functional moiety such as a label, thereby significantly decreasing the expense associated with producing multiple functionalized probes for each desired target sequence. In other words, the probes of the present disclosure only require modification of the target dependent component sequences with respect to each desired target, and the universal component sequences can be kept constant regardless of the target dependent component used. The universal component can comprise conserved sequence that is capable of hybridization with conserved regions of the target dependent component. These conserved regions of the universal component and target dependent component are not specific to the target nucleic acid sequence and are generally arbitrary with respect to the genetic material of the organism being tested (i.e., should not be capable of hybridizing to any other nucleic acids present in the sample). Target specificity is therefore achieved by providing target specific regions in the target dependent component.
In another embodiment, the present disclosure provides a nucleic acid probe comprising a universal functionalized component and a target dependent component such that the probe can be used to detect a large number of target nucleic acids without requiring synthesis of multiple species of functionalized probe. Instead, the target dependent component of the present probe can be modified to provide specificity to the target without requiring modification to the functionalized component thereby providing a more economical approach to probe synthesis.
In one embodiment, the universal component comprises a first universal nucleic acid strand (i.e. first universal oligonucleotide) and a second universal nucleic acid strand (i.e. second universal oligonucleotide) wherein the second universal nucleic acid strand includes at least one region and the first universal strand includes at least one region. In some instances, the universal strand further comprises at least one functional moiety to permit detection of the probe. As discussed further herein, the universal component may comprise only a first universal nucleic acid strand.
In one embodiment, the target dependent component comprises a protector nucleic acid strand (i.e. protector oligonucleotide) and a complement nucleic acid strand (i.e. complement oligonucleotide) wherein the protector strand includes at least one region and the complement strand includes at least two regions. The complement strand, in this embodiment, provides the sequence that is specific for hybridization of the probe to the target nucleic acid sequence.
Referring now to
Still referring to
Referring now to
In one embodiment, the nucleotide sequence of the first region of the second universal strand is at least 60% complementary to the nucleotide sequence of the second region of the protector strand. In this or other embodiments, the nucleotide sequence of the third region of the protector strand is at least 60% complementary to the nucleotide sequence of the fifth region of the complement strand. In these or other embodiments, the nucleotide sequence of the sixth region of the component strand is at least 60% complementary to the nucleotide sequence of the seventh region of the first universal strand. In these or other embodiments, the nucleotide sequence of the first region of the second universal strand is less than 60% complementary to the nucleotide sequence of the seventh region of the first universal strand. In these or other embodiments, the nucleotide sequence of the second region of the protector strand is less than 60% complementary to the nucleotide sequence of the sixth region of the component strand.
In any of the above embodiments, the probe is designed to hybridize to a target nucleic acid sequence T comprising an eighth region and a ninth region as shown in
In any of the above embodiments, upon the X-probe reacting with the target T, complex AC is colocalized with the target. The complex AC is also referred to herein as a target binding component.
In any of the above embodiments, upon the X-probe reacting with the target T, pre-hybridized complex BP that is displaced by the target T is also referred to herein as a protector component.
As used herein, the term “protector” when used to describe a nucleic acid strand, means that such nucleic acid strand is hybridized to the target-binding strand or a portion thereof and is displaced upon hybridization of the complement strand with the target nucleic acid or target nucleotide sequence.
As used herein, the term “region” when referring to the probe means subsequences within the designated strand and should not be understood to denote separate oligonucleotides.
In the above embodiments, the various strands of the present probe may each further comprise one or more additional regions. For example, the second universal strand may further comprise a tenth region and the first universal strand may further comprise an eleventh region wherein at least 60% of the nucleotides of the tenth region are complementary to the aligned nucleotides of the eleventh region. The sequences of the tenth and the eleventh regions, in this instance, are arbitrary and do not depend on the sequence of the target. In another example, the protector strand further comprises a twelfth region between the second region and the third region, and the complement strand further comprises a thirteenth region between the fifth region and the sixth region wherein at least 60% of the nucleotides of the twelfth region are complementary to the aligned nucleotides of the thirteenth region. The sequences of the twelfth and the thirteenth regions, in this instance, are arbitrary and do not depend on the sequence of the target.
In one embodiment, a probe of the present disclosure as described above further comprising a tenth and eleventh region, a first label on the first universal strand and a second label on the second universal strand, and a multi-loop formed at the junction of a different hybridized regions possesses a standard free energy of the hybridization reaction ΔG°r×n to a target nucleic acid sequence that is calculated as:
ΔG°r×nΔG°9-4−ΔG°10-11−ΔG°ML+(ΔG°8-5−ΔG°3-5)−ΔG°label
wherein ΔG°94 is the standard free energy of the hybridization between the ninth region and the fourth region, is the standard free energy of the hybridization between the tenth region and eleventh region, wherein ΔG°8-5 is the standard free energy of the hybridization between the eighth region and the fifth region, wherein ΔG°3-5 is the standard free energy of the hybridization between the third region and the fifth region, wherein ΔG°ML is the standard free energy of the multi-loop formed at the junction of different hybridized regions, and ΔG°label is the standard free energy difference between the thermodynamic contribution of the labels on the first universal strand when they are in close proximity of the second universal strand versus when they are delocalized. In another embodiment, the probe comprises an twelfth and thirteenth region instead of the tenth and eleventh region and does not include a multi-loop such that the probe possesses a standard free energy of the hybridization reaction ΔG°r×n to a target nucleic acid sequence that is calculated as:
ΔG°r×n=ΔG°9-4−ΔG°12-13+(ΔG°8-5−ΔG°3-5)−ΔG°label
wherein ΔG°12-13 is the standard free energy of hybridization between the twelfth region and the thirteenth region.
In yet another embodiment depicted in
ΔG°r×n=ΔG°9-4−ΔG°10-11−ΔG°12-13−ΔG°ML+(ΔG°8-5−ΔG°3-5)−ΔG°label
It should be understood that the calculation of the standard free energy of hybridization ΔG°r×n can be modified from what is provided herein based on the absence or presence of optional regions and structural features, such as the tenth and eleventh regions and the multi-loop structure, which are only present in certain embodiments of the present probe. Thus, the equations provided herein may be modified to not include these terms. Similarly, various other structures or regions not described herein may be added to the probe such that the standard free energy calculations may need to include other terms to account for such changes. The description provided herein for calculating the standard free energy is sufficient to permit one skilled in the art to make such modifications to the calculations in view of any such changes in probe structure.
In any of the above embodiments, the sequences of the regions can be designed such that the interaction between the probe and the target possesses a standard free energy ΔG°r×n within −4 kcal/mol to +4 kcal/mol, or a standard free energy that determined by ΔG°r×n is within 5 kcal/mol of the standard free energy that determined by equation −Rτ ln([BP]/[BPCA]), wherein R is the ideal gas constant, τ is temperature in Kelvin, [BP] is the final concentration of complex BP in X-probe solution, and [BPCA] is the final concentration of the X-probe in solution. For embodiments possess a reaction standard free energy ΔG°r×n within −4 kcal/mol to +4 kcal/mol, the standard free energy determined by Expression (ΔG°9-4−ΔG°12-13+(ΔG°8-5−ΔG°3-5)) is not between −4 kcal/mol and +4 kcal/mol, and the standard free energy determined by Expression (ΔG°9-4−ΔG°12-13+(ΔG°8-5−ΔG°3-5)+Rτ ln([BP]/[BPCA]) is not between −5 kcal/mol and +5 kcal/mol. Note that the energy term is defined to be zero if the denoted regions do not exist.
In any of the above embodiments, the probe of the present invention may further comprise a functionalized chemical moiety is conjugated to the 5′ end, to the 3′ end, or to an internal nucleotide of the first universal strand and may also comprise the same on the second universal strand. For example, a fluorophore moiety is conjugated to the first universal strand and a fluorescence quenching moiety is conjugated to the second universal strand. In one embodiment, the fluorophore is within 4 nm of a fluorescence quenching moiety. Additionally, the first universal strand and second universal strand may comprise multiple fluorophore moieties and multiple fluorescence quenching moieties, respectively, wherein the fluorophore is within 4 nm of a quenching moiety. In an alternative embodiment, one or more fluorophore moieties may be conjugated to the second universal strand and one or more quenching moieties may be conjugated to the first universal strand and wherein, the one or more fluorophores may be within 4 nm of the one or more quenching moieties.
In any of the above embodiments, the probe may further comprise any combination of the group consisting of: at least one extra single stranded region between the second region and the third region; between the fifth region and the sixth region; between the tenth region and the first region; between the seventh region and the eleventh region; between the second region and the twelfth region; and between the thirteenth region and the sixth region.
In any of the above embodiments, the probe may comprise a stoichiometric ratio of the protector component (the second universal strand and the protector strand) to probe (comprising protector component and target binding component—first universal strand and complement strand) from about 0.001:1 to about 1000:1.
In one embodiment, a probe is provided comprising a first universal strand, a second universal strand, a protector strand, a complement strand, and at least one auxiliary nucleic acid strand, wherein the second universal strand is indirectly colocalized to the protector strand by the at least one auxiliary nucleic acid strand. In one embodiment, the sequences of the auxiliary nucleic acid strand are arbitrary and do not depend on the sequence of the target.
In another embodiment, a probe is provided comprising a first universal strand, a second universal strand, a protector strand, a complement strand, and at least one auxiliary nucleic acid strand, wherein the first universal strand is indirectly colocalized to the complement strand by the at least one auxiliary nucleic acid strand. In one embodiment, the sequences of the auxiliary nucleic acid strand are arbitrary and do not depend on the sequence of the target.
In any of the above embodiments, any one of the strands of the probe may further comprise a synthetic nucleic acid analog such as LNA, PNA, 2′O-methyl substituted RNA, L-DNA, and speigelmers. In an alternative, any one of the strands of the probe may further comprise synthetic or natural analogs such as isosine, methylated nucleotides, iso-cytosine and iso-guanine, spiegelmer nucleotides, and xDNA.
A process for preparing any of the above embodiments of the present probe is provided. In one embodiment, the first universal strand (A), the second universal strand (B), the protector strand (P), and the complement strand (C) are mixed together in aqueous solution. In one embodiment, the concentration of the complement strand is in excess of the first universal strand, the concentration of the protector strand is in excess of the complement strand, and the concentration of the second universal strand is in excess of the protector strand such that a probe mixture is formed comprising complex BPCA, complex BPC, complex BP, and strand B. In another embodiment, the concentration of the protector strand is in excess of the second universal strand, the concentration of the complement strand is in excess of the protector strand, and the concentration of the first universal strand is in excess of the specific complement strand such that a probe mixture formed comprises complex BPCA, complex PCA, complex CA, and strand A.
In any of the above embodiments, the probe components are thermally annealed following mixing. In one embodiment, the thermal annealing includes heating the mixture to a temperature no less than 65° C., and cooling to a temperature no higher than 45° C. In another embodiment, the thermal annealing includes heating the mixture to a temperature no less than 80° C., and cooling to a temperature no higher than 60° C. In yet another embodiment, the thermal annealing includes heating the mixture to a temperature no less than 95° C., and cooling to a temperature no higher than 75° C.
In an alternative embodiment, the probe components are isothermally annealed through addition of salt or high salinity solutions. In yet another embodiment, the probe components are isothermally annealed through removal or dilution of formamide or other denaturants.
The probes of the present disclosure can be used in a variety of assays including, but not limited to the following: specific DNA or RNA detection or quantitation via fluorescence; specific DNA or RNA imaging via fluorescence; specific DNA or RNA detection, quantitation, or imaging via chromagenic methods (e.g. haptenated probes, and subsequent antibody-based recruitment of horseradish peroxidase (HRP) or alkaline phosphate (AP)); real-time DNA or RNA quantitation, such as through quantitative PCR; and DNA or RNA capture via biotin-streptavidin, gold-thiol, click chemistry, or other chemistries.
Thus, in yet another embodiment, a method for detecting a sequence variance in a sample of nucleic acid is provided. The method comprises introducing a probe of the present disclosure into a sample comprising nucleic acid. The probe can be any probe that has been described herein comprising a complement oligonucleotide that is specific for the sequence variance that is desired to be detected. The “introducing” step should be understood to comprise any method known in the art for administering a nucleic acid probe to a sample containing nucleic acid. The method may further comprise thermal annealing steps as described above prior to the introducing step in order to permit the various oligonucleotide components of the probe to anneal. Additionally, there may be additional thermal cycling steps following the introduction of the probe to the sample in accordance with polymerase chain reaction or other nucleic acid hybridization protocols for causing the probe to base pair with the target. Finally, in the instance a label such as a fluorophore is conjugated to a universal oligonucleotide of the probe, the method further comprises either imaging the sample to detect the fluorophore signal or collecting data based on the level of fluorescence produced as a result of the probes interaction with the target.
All regions described above (first region, second region, third region, etc.) should be understood to reference the particular region of the particular strand as described above throughout this disclosure. For example, “first region” as used herein should be understood to refer to the above described region of the second universal strand throughout this disclosure.
Referring now to
Thus, the ability to colocalize target T to a functionalized oligonucleotide A of completely independent sequence has important economic implications, as the same oligonucleotide A can be mass-produced for function with any or many different sequences of T via the specificity provided by the specific complementary strand. Many different chemical moieties could potentially be functionalized to first universal strand A—for example, a fluorophore, a biotin, a digoxigenin or other hapten, a thiol, a N-hydroxysuccinimide group, or an alkyne or azide group.
Referring now to
Referring now to
In this example preparation process, the stoichiometry (5:3:1.5:1) was selected, but it should be understood that many different stoichiometries could be used. In this example preparation process, the salinity of the buffer (0.75 M Na+) was selected, but an aqueous solution with no less than 50 mM of a monovalent cation (such as Na+) or 1 mM of a divalent cation (such as Mg2+) could be used. In this example preparation process, the thermal annealing protocol was selected, but various different heating and cooling profiles may be used. Alternatively, thermal annealing may be skipped altogether and the components could be added to a sample independently.
High target-binding specificity of the probe of the present disclosure is achieved at equilibrium when the reaction standard free energy (ΔG°r×n) is within −4 and +4 kcal/mol, in entropically balanced reactions with equal numbers of reactant and product species. The reaction standard free energy ΔG°r×n can be calculated by summing a number of ΔG° terms corresponding to the thermodynamics of different parts of the X-probe (e.g. binding between complementary regions), as follows:
ΔG°r×n=ΔG°9-4−ΔG°10-11−ΔG°12-13−ΔG°ML+(ΔG°8-5−ΔG°3-5)−ΔG°label
In the above equation, the energy terms with subscripted by numbers represent the standard free energy of the hybridization between the two referenced regions. For example, the term ΔG°9-4 represents the standard free energy of the hybridization between the ninth region (in target T) and the fourth region in the complement strand of the present probe. The term ΔG°ML represents the standard free energy of the multi-loop formed at the junction of the four paired helixes. The term ΔG°label represents the standard free energy difference between the thermodynamic contribution of the labels on the first universal strand when they in close proximity of the second universal strand versus when they are delocalized. It should be noticed that the energy term is defined to be zero if the denoted regions do not exist.
The standard free energy of the hybridization between regions of the various strands of the present probe is calculated by using the nearest neighbor model as described in Santa Lucia, J. & Hicks, D. The thermodynamics of DNA structural motifs. Annu Rev Biophys Biomol Struct 33, 415-440 (2004) for DNA and Sugimoto, N. et al. Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes. Biochemistry 34, 11211-11216 (1995) for RNA. In this method, two adjacent base pairs comprise one stack, with reported enthalpy (ΔH°) and entropy (ΔS°) values for DNA and RNA. The standard free energy of each stack at temperature τ is calculated as ΔG°=ΔH°−τΔS°. The standard free energy of a hybridized helix can be evaluated by summing all the stack energies.
Specifically, ΔG°9-4 comprises the standard free energy of all the stacks in duplex 9-4 (i.e. in the ninth (9) region of the target nucleic acid hybridized to the fourth (4) region of the specific complement strand), the standard free energy of the neighboring stack at the junction between duplex 9-4 and duplex 3-5 (third and fifth regions), and the thermodynamic penalty of hybridization initiation (ΔG°init), due to the entropy loss of orienting two nucleic acid molecules for hybridization. The value of ΔG°init can be calculated based on the published parameters of ΔH°init and ΔS°init.
ΔG°10-11 comprises the standard free energy of all the stacks in duplex 10-11 (tenth region and eleventh region).
ΔG°12-13 comprises the standard free energy of all the stacks in duplex 12-13 (twelfth region and thirteenth region) and the standard free energy of the neighboring stack at the junction between duplex 12-13 and duplex 3-5.
ΔG°8-5 comprises the standard free energy of all the stacks in duplex 8-5.
ΔG°3-5 comprises the standard free energy of all the stacks in duplex 3-5 and the thermodynamic penalty of hybridization initiation (ΔG°init).
The standard free energy of the multi-loop ΔG°ML can be evaluated by published online software such as that described in Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415 (2003) (mfold). For example, and the thermodynamic effect of multi-loop composed by the exact sequences as shown in our examples is about +4.5 kcal/mol (37° C., 0.75 M Na+, calculated by mfold).
It has been known that the functionalized groups can have significant thermodynamic effects, stabilizing or destabilizing nucleic acid hybridization. Although the energy ΔG°label cannot be calculated precisely, it can be experimentally characterized. For example, we observed the thermodynamic effect of interaction between the ROX fluorophore and the RQ quencher is between −3 to −4 kcal/mol (37° C., 0.75 M Na+).
We have previously shown in PCT application number PCT/US14/52827, the contents of which are incorporated herein by reference, that the probe behavior can be fine-tuned post-synthesis by tuning the ratio of the concentration of the various components of the probe in solution. Furthermore, for more basic explanation on the interaction between the target and probes comprising a complex of a complement strand and a protector strand, see published international application no. WO2012058488, which is incorporated by reference herein in its entirety.
As applied to our current invention, a good tradeoff between specificity and sensitivity is achieved when the standard free energy determined by Expression 1 (ΔG°r×n) is within 5 kcal/mol of the standard free energy determined by Expression −Rτ ln([BP]/[BPCA]) wherein R is the ideal gas constant, τ is the temperature in Kelvin, [BP] is the final concentration of the complex BP in solution, and [BPCA] is the final concentration of the X-probe in solution.
In practice, the concentration of BP can be rationally determined such that the complex BP is in excess of the complex BPCA to improve the specificity of the X-probe. Furthermore, the lengths and sequences of the regions in the X-probe component oligonucleotides can be rationally designed to achieve ΔG°r×n within −4 kcal/mol and +4 kcal/mol.
When the highly specific X-probe is designed to be conditionally fluorescent, additional design criteria of fluorescence quenching ratio will impact the design of the optional regions 10, 11, 12, and 13.
In general, to ensure that the complex BP can be fully displaced by the target molecule in the operational temperatures and salinity conditions, the length of the optional regions need to be short enough such that the first universal strand and the second universal strand cannot form stable partially double-stranded complex via the hybridization between region 10 and region 11. However, if the lengths of the region 10 and region 11 are too short, the fluorophore and the quenching moiety might not be within 4 nm from each other, increasing the fluorescence background. Therefore, the base pairs of optional regions need to be distributed according to the operation temperatures and salinity condition. In the examples described below, the length of regions 10 and 11 were selected to be 7 nucleotides, in consideration of the operational temperature of 37° C. and operational salinity of 0.75 M Na+.
In addition to use of an individual X-probe for detection of a single target sequence, potentially in a background of other nucleic acids with similar sequence, multiple X-probes can simultaneously exist in solution and be used for parallel detection of multiple analyte sequences as provided in
The ability to easily construct pools of X-probes to simultaneously probe multiple target nucleic acid sequences has important implications for clinical diagnostics. For example, there are many known cancer mutations such as those reported in Forbes, S. et al. COSMIC 2005. Br. J. Cancer 94, 318-322 (2006), and any particular cancer patient will only have a small subset of the known mutations. Thus, X-probes against known mutations can be pooled together, such that any significant fluorescence response will indicate the presence of at least one cancer mutation, and by implication existence or increased risk of tumors in the body. As another example, certain strains of infectious diseases possess different antibiotics resistances, and these resistances can be conferred via mutations on different genes; parallel X-probe detection of mutations in any antibiotics resistance genes can help enable accurate infectious disease diagnostics and profiling.
In an alternative embodiment, multiplexed detection of different targets is provided. Referring now to
One advantage of the present probe system is the concept of decoupling the sequence of the functionalized strand from the sequence of the target. Many different variants of the basic X-probe design should function similarly. These variants are provided in
Referring now to
Referring now to
Alternatively, the morphology of the first universal strand A or second universal strand B may differ from embodiments described earlier, for example by incorporating additional regions or strands as shown in (panel B) of
Finally, a number of reduced designs also function in the spirit of the X-probes by removing one or more of the regions and strands, in the case where only the first universal strand is functionalized, and not the second universal strand (panel C).
In this example, a conditionally-fluorescent X-probe of the present disclosure is used to identify the presence of a target nucleic acid in a sample. Referring now to
The experiment was conducted in 1200 μL cuvette with appropriate buffer (typically 5×PBS). X-probe solution is incubated in the cuvette in Horiba Fluoromax-4 machine for 20 minutes to allow temperature equilibration before the start of data acquisition. The buffer and X-probe are further incubated in the cuvette for an additional 5 to 20 minutes after fluorescence data acquisition begins in order to establish the background fluorescence. Subsequently, the cuvettes are removed from the machine and target solutions (short synthetic oligonucleotide depicted as target T of the
As demonstrated in the inset of
In this example, three different conditionally-fluorescent X-probes of the present disclosure (with common universal strands A and B) are used to identify the presence of three different target nucleic acids (sequence for TP53 carrying the R273C (c.817C>T) mutation—
As can be seen in the panels on
In addition to the examples described above and depicted in
These experimental results are summarized in
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” As used herein “another” may mean at least a second or more.
It is contemplated that any instance discussed in this specification can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve the methods of the invention.
Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive.
As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
Each probe system described herein may be comprised of DNA, RNA, or analogs thereof, and/or combinations thereof. In certain instances, a probe system comprises one or more non-natural nucleotides. The incorporation of non-natural nucleotides in the primers can further augment the performance of the probe systems, such as by providing improved per-base binding affinity and increased nuclease resistance.
A “target” for a probe system described herein can be any single-stranded nucleic acid, such as single-stranded DNA and single-stranded RNA, including double-stranded DNA and RNA rendered single-stranded through heat shock, asymmetric amplification, competitive binding, and other methods standard to the art. A “target” for a primer system can be any single-stranded (ss) or double-stranded (ds) nucleic acid, for example, DNA, RNA, or the DNA product of RNA subjected to reverse transcription. In some instances, a target may be a mixture (chimera) of DNA and RNA. In other instances, a target comprises artificial nucleic acid analogs, for example, peptide nucleic acids (Nielsen et al. Science 254(5037): 1497-500 (1991)) or locked nucleic acids (Alexei et al. Tetrahedron 54(14): 3607-30 (1998)). In some instances, a target may be naturally occurring (e.g., genomic DNA) or it may be synthetic (e.g., from a genomic library). As used herein, a “naturally occurring” nucleic acid sequence is a sequence that is present in nucleic acid molecules of organisms or viruses that exist in nature in the absence of human intervention. In some instances, a target is genomic DNA, messenger RNA, ribosomal RNA, micro-RNA, pre-micro-RNA, pro-micro-RNA, long non-coding RNA, small RNA, epigenetically modified DNA, epigenetically modified RNA, viral DNA, viral RNA or piwi-RNA. In certain instances, a target nucleic acid is a nucleic acid that naturally occurs in an organism or virus. In some instances, a target nucleic is the nucleic acid of a pathogenic organism or virus. In certain instances the presence or absence of a target nucleic acid in a subject is indicative that the subject has a disease or disorder or is predisposed to acquire a disease or disorder. In certain instances the presence or absence of a target nucleic acid in a subject is indicative that the subject will respond well or poorly to a treatment, such as a drug, to treat a disease or disorder. In certain instances the presence or absence of a target nucleic acid in a subject is indicative that the subject who has been treated previously for cancer and is in remission may be at risk of cancer recurrence.
The terms “polynucleotide,” “nucleic acid,” “strand,” “oligonucleotide,” and “nucleic acid molecule” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. A polynucleotide may be further modified, such as by conjugation with a labeling component. The term “recombinant” polynucleotide means a polynucleotide of genomic, cDNA, semi-synthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a non-natural arrangement. The term “isolated nucleic acid” refers to a polynucleotide of natural or synthetic origin or some combination thereof, which (1) is not associated with the cell in which the “isolated nucleic acid” is found in nature, and/or (2) is operably linked to a polynucleotide to which it is not linked in nature.
A nucleic acid may also encompass single- and double-stranded DNA and RNA, as well as any and all forms of alternative nucleic acid containing modified bases, sugars, and backbones. The term “nucleic acid” thus will be understood to include, but not be limited to, single- or double-stranded DNA or RNA (and forms thereof that can be partially single-stranded or partially double-stranded), cDNA, aptamers, peptide nucleic acids (“PNA”), 2′-5′ DNA (a synthetic material with a shortened backbone that has a base-spacing that matches the A conformation of DNA; 2′-5′ DNA will not normally hybridize with DNA in the B form, but it will hybridize readily with RNA), and locked nucleic acids (“LNA”). Nucleic acid analogues include known analogues of natural nucleotides that have similar or improved binding, hybridization of base-pairing properties. “Analogous” forms of purines and pyrimidines are well known in the art, and include, but are not limited to aziridinylcytosine, 4-acetylcytosine, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-Methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N.sup.6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid, and 2,6-diaminopurine. DNA backbone analogues provided herein include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3′-thioacetal, methylene(methylimino), 3′-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs), methylphosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup, 1997, Biochemistry 36:8692-8698), and benzylphosphonate linkages, as discussed in U.S. Pat. No. 6,664,057; see also OLIGONUCLEOTIDES AND ANALOGUES, A PRACTICAL APPROACH, edited by F. Eckstein, IRL Press at Oxford University Press (1991); Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and Denhardt (NYAS 1992); Milligan, 1993, J. Med. Chem. 36: 1923-1937; Antisense Research and Applications (1993, CRC Press). The nucleic acids herein can be extracted from cells or synthetically prepared according to any means known to those skilled in the art; for example, the nucleic acids can be chemically synthesized or transcribed or reverse transcribed from cDNA or mRNA, among other sources.
A target nucleic acid utilized herein can be any nucleic acid, for example, human nucleic acids, bacterial nucleic acids, or viral nucleic acids. A target nucleic acid sample or sample comprising a target nucleic acid can be, for example, a nucleic acid sample from one or more cells, tissues, or bodily fluids. Target samples can be derived from any source including, but not limited to, eukaryotes, plants, animals, vertebrates, fish, mammals, humans, non-humans, bacteria, microbes, viruses, biological sources, serum, plasma, blood, urine, semen, lymphatic fluid, cerebrospinal fluid, amniotic fluid, biopsies, needle aspiration biopsies, cancers, tumors, tissues, cells, cell lysates, crude cell lysates, tissue lysates, tissue culture cells, buccal swabs, mouthwashes, stool, mummified tissue, forensic sources, autopsies, archeological sources, infections, nosocomial infections, production sources, drug preparations, biological molecule productions, protein preparations, lipid preparations, carbohydrate preparations, inanimate objects, air, soil, sap, metal, fossils, excavated materials, and/or other terrestrial or extra-terrestrial materials and sources. The sample may also contain mixtures of material from one source or different sources. For example, nucleic acids of an infecting bacterium or virus can be amplified along with human nucleic acids when nucleic acids from such infected cells or tissues are amplified using the disclosed methods. Types of useful target samples include eukaryotic samples, plant samples, animal samples, vertebrate samples, fish samples, mammalian samples, human samples, non-human samples, bacterial samples, microbial samples, viral samples, biological samples, serum samples, plasma samples, blood samples, urine samples, semen samples, lymphatic fluid samples, cerebrospinal fluid samples, amniotic fluid samples, biopsy samples, needle aspiration biopsy samples, cancer samples, tumor samples, tissue samples, cell samples, cell lysate samples, crude cell lysate samples, tissue lysate samples, tissue culture cell samples, buccal swab samples, mouthwash samples, stool samples, mummified tissue samples, autopsy samples, archeological samples, infection samples, nosocomial infection samples, production samples, drug preparation samples, biological molecule production samples, protein preparation samples, lipid preparation samples, carbohydrate preparation samples, inanimate object samples, air samples, soil samples, sap samples, metal samples, fossil samples, excavated material samples, and/or other terrestrial or extra-terrestrial samples. In some instances, a target nucleic acids utilized herein comprise repetitive sequence, secondary structure, and/or a high G/C content.
In certain instances, a target nucleic acid molecule of interest is about 10 to about 1,000,000 nucleotides (nt) in length. In some instances, the target is about 19 to about 100, about 100 to about 1000, about 1000 to about 10,000, about 10,000 to about 100,000, or about 100,000 to about 1,000,000 nucleotides in length. In some instances, the target is about 20, about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1,000, about 2,000, about 3,000, about 4,000, about 5,000, about 6,000, about 7,000, about 8,000, about 9000, about 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, about 100,000, about 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, or about 1,000,000 nucleotides in length. It is to be understood that the target nucleic acid may be provided in the context of a longer nucleic acid (e.g., such as a coding sequence or gene within a chromosome or a chromosome fragment).
In certain instances, a target of interest is linear, while in other instances, a target is circular (e.g., plasmid DNA, mitochondrial DNA, or plastid DNA).
Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. While numerous changes may be made by those skilled in the art, such changes are encompassed within the spirit of this invention as illustrated, in part, by the appended claims.
The present application is a continuation application of International Application No. PCT/US15/13450, filed Jan. 29, 2015, which claims priority to U.S. Provisional Application No. 61/932,898 filed Jan. 29, 2014, which is incorporated herein by reference in its entirety.
This invention was made with government support under Award No. EB015331 awarded by NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB). The government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 61932898 | Jan 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US15/13450 | Jan 2015 | US |
| Child | 15216214 | US |
